Please login to the form below

Not currently logged in
Email:
Password:

Terrosa

This page shows the latest Terrosa news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Merck & Co's Lantus biosimilar

CHMP recommends Merck & Co's Lantus biosimilar

Hungarian pharmaceutical firm Gedeon Richter and Germany's Stada Arzneimittel received recommendations for Terrosa and Movymia respectively, for the treatment of postmenopausal women and men at increased risk of fracture.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics